http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
飼料資源開發을 위한 雜灌木樹葉의 飼料價値와 韓牛의 放牧利用에 關한 硏究
尹益錫,陸完芳,李仁德,曺圭燉,金炯基 건국대학교 1978 學術誌 Vol.22 No.1
As a part of forestry utilization for livestock feed resources the feeding value ague of shrub leaf by growth stage and grazing behabiour of the native cattle at shrubby grassland in function of seasons were investigated and the following results were obtained. 1. The crude protein content of oak leaf declined as the growth stage increased whereas the contents of crude fiber and crude fat showed the opposite tendency. 2. The intake of oak leaf paralleled with the amount given while the intake of the mixed grass leas remarkable increased and the body weight gain was also remarkably increased. 3. The average number of oak leaf intake was 70.5 times for spring, 148.7 for summer, and 395.7 for autumn. 4. The grazing time by the native cattle was decreased in the order of spring, autumn, and summer. As for the grazing behaviour, the intake activity was most active during morning, mid-day and late afternoon or three times a day. 5. The duration of rumination was found to be in the decreasing order or summer, autumn and spring, cattles ruminated more when the grasses were more abundant. 6. As for the inactive period of animal, it was short during spring when the animals spent more time for eating but it was about 5 times longer during both summer and autumn.
녹동균 세포외막 단백질 백신 CFC-1-101의 안정성 및 면역원성 검토 : 임상 제 Ⅰ/Ⅱa상 시험
장인진,김익상,유경상,임동석,김형기,신상구,장우현,박완제,이나경,정상보,안동호,조양제,안보영,이윤하,김영지,남성우,김현수 대한감염학회 1998 감염 Vol.30 No.3
목적 : 제일제당에서는 녹농균의 세포외막 단밸질을 유효성분으로 하는 백신인 CFC-101을 개발하였으며, 동물시험에서 이 백신의 안전성과 유효성을 입증하였다. 본 연구에서는 이 녹농균 백신의 인체에 대한 안전성과 면역원성을 평가하는 동시에 인체 접종시의 최적 투여 용량을 결정하기 위하여 제 I/Ⅱa상 임상시험을 수행하였다. 방법 : 건강한 성인 남자를 피험자로 선별하여 각 용량군에 백신투여자 6명, 위약투여자 2명을 배정하였다. 백신 투여군은 0.25mg, 0.5mg 또는 1.0mg 용량의 녹농균 백신을 7일 간격으로 3회에 걸쳐 근육주사 하였으며, 위약 투여군에게는 세포외막 단백질을 제외한 동일한 성분을 투여하였다. 백신접종 후 국소적 또는 전신적인 반응의 발생여부를 관찰하고, 혈액시료를 체취하여 백신의 역가와 유효성을 검정하였다. 결과 : 녹농균 백신 CFC-101은 모든 접종자에서 양호한 내약성을 보였다. 또한 0.5mg 과 1.0mg 백신 투여군에서는 100%의 항체양전율을 나타내었다. 생성된 항체는 녹농균 세포외막단백질에 특이성을 보였고, 녹농균 감염에 대해 방어효능이 있었다. 결론 : 이와같은 결과로부터 이 녹농균 백신은 인체에 안전하게 투여할 수 있으며, 높은 항체 생성능으로 감염방어 효능을 보이고 0.5mg과 1.0mg이 최적용량인 것으로 판단되었다. Background : We developed a Pseudomonas aeruginosa outer membrane protein(OMP) vaccine CFC-101, and the prophylactic efficacy of which has been demonstrated in animal models. In order to evaluate the safety and immunogenicity of the P. aeruginosa vaccine, we carried out a phase I/Ⅱa clinical trial in healthy male volunteers. Methods : Groups of eight volunteers, including two placebo subjects, were vaccinated intramuscularly with three doses of 0.25, 0.5 or 1.0 mg of the vaccine at one week intervals. Sings of systemic and local reactions observed after vaccination were recorded for each vaccinee for 5 days. Physical examinations were performed on days 0, 1, 7, 8, 14, 15, 21, and 42, and clinical laboratory tests were done on days 0, 3, and 21. Blood samples for assay of serum antibody levels were obtained up to 42 days after the first vaccination. Results : The vaccine was generally well tolerated by all vaccinees, showing no significant side effects. In the three dosage groups, all vaccinees, except one receiving the 0.25 mg dose, showed significant elevation in serum IgG antibody titers against the vaccine proteins, indicating 100% seroconversion in 0.5 and 1.0 mg groups. The human antibodies induced by the vaccine were specific for P. aeruginosa OMPs, as confirmed by western blot analysis and immunoprecipitation assays. The capacity of the human antisera to enhance opsonophagocytic killing activity by polymorphonuclear leukocytes and to confer protection against P. aeruginosa infections indicates that the antibodies elicited by the vaccine have protective efficacy. Conclusion : We conclude that the P. aeruginosa OMP vaccine is safe and effective for human use and its optimal dose to be 0.5 or 1.0 mg.
조완익 ( Wan Ik Cho ),김현규 ( Hyun Kyu Kim ),박주희 ( Juhee Park ),박귀영 ( Kui Young Park ),임윤영 ( Yoon Young Lim ),김영희 ( Young Heui Kim ),김기호 ( Ki Ho Kim ),김형미 ( Hyung Mi Kim ),이갑석 ( Kapsok Li ),김범준 ( Beom Joon 대한천식알레르기학회 2012 천식 및 알레르기 Vol.32 No.1
Background: Houttuynia cordata has long been used in traditional oriental medicine for the treatment of inflammatory disease. In the present study, we investigated the anti-inflammatory effect of Houttuynia cordata extracts on Raw 264.7 cells, which is activated with lipopolysaccharide (LPS) and interferon-γ (IFN-γ). Methods: We treated LPS-and IFN-γ-activated murine macrophage Raw 264.7 cells with extracts of Houttuynia cordata and measured the production of nitric oxide (NO) and prostaglandin E2 (PGE2), and the expression of inducible nitric oxide synthase (iNOS), cyclooxygenase (COX)-2, and pro-inflammatory cytokines (Interleukin [IL]-1α, IL-1β, IL-4, IL-6, IL-10, IL-12, tumor necrosis factor-α, regulated on activation normal T-cell expressed and secreted) in activated Raw 264.7 cells after treatment with Houttuynia cordata extracts. Results: NO formation by activated Raw 264.7 cells was reduced in response to Houttuynia Cordata in a dose-dependent manner. Formation of PGE2, a final product of the COX pathway was reduced by Houttuynia cordata extracts and reduction in COX-2 expression was proportional to the reduction in PGE2. The expression of proteins, iNOS and COX-2 decreased with increasing concentration of Houttuynia cordata extracts. The related pro-inflammatory cytokines did not decrease in the cells treated with Houttuynia cordata extracts. Conclusion: Houttuynia Cordata extracts suppressed the production of NO and PGE2 and decreased the expression of iNOS and COX-2. It has potential for the treatment of inflammatory diseases. Further studies are needed to elucidate the effects of Houttuynia Cordata extracts on the production of inflammatory cytokines. (Korean J Asthma Allergy Clin Immunol 2012;32:43-50)